Circulomics is a Maryland biotechnology company located within Johns Hopkins' FastForward Business Accelerator that spun out of the $14M Cancer Center of Nanotechnology Excellence. Our vision is to commercialize a large portfolio of micro-, nano-, and single molecule technologies that will streamline every step in the biomarker workflow from front-end sample preparation to assays and detection instruments. These technologies include our Nanobind DNA/RNA extraction technology, Ligo-miR microRNA assay technology, and PicoSep single molecule analysis system.
In recent years, microRNA biomarkers have been propelled to the forefront of medical research based on their unparalleled ability to accurately identify cancer and other disease states. Circulomics has received $2.8M in grant funding to develop innovative platforms for microRNA profiling, single molecule analysis, and nucleic acid extraction that will drive the research and rapid clinical translation of these promising biomarkers.